OR WAIT null SECS
The new Europe headquarters will be the hub for the company’s European operations, including production of product.
QurAlis, a clinical-stage biotechnology company located in Cambridge, Mass., announced on Jan. 3, 2024 the opening of its European Union (EU) headquarters in Leiden, The Netherlands. The location will serve as a European hub for operations that include clinical trials through commercialization of the company’s products. QurAlis’ product pipeline includes therapies to treat neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). QurAlis focuses on treatments for “patients who have a loss of Kv7.2/7.3, patients who have loss of STATHMIN-2, as well as patients with loss of UNC13A and impairment in synaptic signaling.”
“The expansion of our operations into Europe represents a new chapter for QurAlis, building upon the tremendous momentum of our organization,” said Kasper Roet, CEO and co-founder of QurAlis, in a press release. “In a short period of time, QurAlis has made significant progress with regulatory approvals for our clinical programs in the EU, Canada, and the UK [United Kingdom]. The successful completion of the quality systems inspection by the Dutch regulatory agency will allow us to directly leverage our world-class ASO manufacturing expertise and control our end-to-end production supply chain. With our new European headquarters, and the skilled talent network in Leiden and the region, we will further strengthen our position as we bring breakthrough precision medicines to patients with ALS, FTD, and other neurodegenerative diseases.”
“QurAlis’ new location in Leiden is designed to not just meet our current needs, but also to scale with our business as we continue to grow,” said Hagen Cramer, chief technology officer of QurAlis, in the release. “Our new European headquarters will allow us to release ASOs and other products into the European market for our programs so that we can deliver innovative solutions and make a meaningful difference in patients’ lives.”